@misc{10481/69456,
year = {2021},
url = {http://hdl.handle.net/10481/69456},
abstract = {Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis
(RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms
(SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in
pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian
patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype
(FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01–5.92) at 12 months
and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19–8.66) and 12 months (OR = 6.62;
95% CI = 1.25–46.89) of treatment with ABA. A tendency was observed towards an association
between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA
after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the lowaffinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59;
95% CI = 1.01–2.58). The clinical variables associated with better response to ABA were lower age
at starting ABA (OR = 1.06; 95% CI = 1.02–1.11) and greater duration of ABA treatment (OR = 1.02;
95% CI = 1.01–1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98–0.99),
non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53;
95% CI = 3.46–523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02–0.47),
monotherapy (OR = 19.22; 95% CI = 2.05–343.00), lower initial patient’s visual analogue scale (PVAS)
value (OR = 0.95; 95% CI = 0.92–0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87–0.97). This
study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant,
and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further
studies will be required to confirm these results.},
organization = {Fundación de Investigación Biosanitaria de Andalucía Oriental (FIBAO)},
organization = {University
of Granada},
organization = {ERDF
funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039},
publisher = {MDPI},
keywords = {Rheumatoid arthritis},
keywords = {Abatacept},
keywords = {FCGR2A},
keywords = {FCGR3A},
keywords = {Effectiveness},
keywords = {Polymorphisms},
title = {Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis},
doi = {10.3390/jpm11060573},
author = {Márquez Pete, Noelia and Maldonado Montoro, María del Mar and Pérez Ramírez, Cristina and Martínez Martínez, Fernando and Martínez de la Plata, Juan Enrique and Daddaoua, Abdelali and Jiménez Morales, Alberto},
}